1 **Evaluation of Six Commercial and Non-Commercial Colistin Resistance Diagnostics** Tumisho Mmatumelo Seipei Leshaba^a, Masego Mmatli^a, Lebogang Skosana^{ab}, Nontombi 2 Marylucy Mbelle^a, John Osei Sekyere ^{#acd} 3 ^a Department of Medical Microbiology, School of Medicine, University of Pretoria, South 4 Africa. 5 ^b Department of Medical Microbiology, Tshwane Academic Division, National Health 6 Laboratory Service, Pretoria, South Africa 7 8 ^c Department of Dermatology, School of Medicine, University of Pretoria, South Africa ^d Institute of Biomarker Research, Medical Diagnostic Laboratories, Genesis Biotechnology 9 10 Group, Hamilton, NJ, United States 11 #Address correspondence to Dr. John Osei Sekyere, Department of Dermatology, School of 12 Medicine, University of Pretoria, 0084 Pretoria, South Africa: j.oseisekyere@up.ac.za; 13 jod14139@gmail.com 14 15 **Running head:** Evaluation of colistin resistance diagnostic tests. 16 Tweet: "Vitek 2, Sensititre, and ComASP colistin proved superior colistin MIC tests when 17 evaluated among six tests. The Rapid NP test was comparatively efficient with a shorter 18 turnaround time, albeit with higher very major errors." 19 20 21 22

Abstract **Background.** Resistance to colistin, a last-reserve antibiotic used for treating drug-resistant infections, is increasing globally. This study evaluated six diagnostic tests designed to detect colistin-resistant pathogens. **Methods.** PCR and broth microdilution assays (BMD) were used to respectively characterize the molecular mechanisms and phenotypic colistin resistance of 142 Gram-negative bacterial isolates and controls. The sensitivity, specificity, positive- and negative-predictive values, major (ME) and very major errors (VME), categorical and essential agreements (EA) of ComASP Colistin, CHROMagar COL-APSE, Rapid NP Test, Sensititre, MicroScan, and Vitek 2 were determined with these isolates; the BMD was used as gold standard. Results. The Vitek 2, Sensititre, and ComASP tests were more efficient, albeit with concerning ME and VMEs and low EAs. Sensititre was 100% specific with 0% ME and 3.61% VME; Vitek 2 had the least VME (1.25% and 0%) and a low EA (57.50%). ComASP had an EA of 75.35%. MicroScan was highly sensitive (96.55%) but less specific (87.50%), with very below-accetable EAs (48.11%). The CHROMAgar COL-APSE efficiently identified the species with their unique colours but was the least specific (67.80%), with the highest ME (32.20%) and high VME (7.23%). The Rapid NP test had the highest VME (7.84%), producing results within 4 hours with 92.16% sensitivity and 96.08% specificity. Conclusion: Vitek 2, MicroScan, ComASP colistin, and Sensititre are good for determining colistin resistance; the latter two tests are recommendable for low-resourced laboratories. The in-house Rapid NP test has short turnaround time with high efficiency for initial resistance screening.

Keywords: colistin resistance; tests; assays; polymyxins; *Enterobacterales*.

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

Introduction

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

Increasing use of carbapenems to treat multidrug-resistant bacterial infections invariably led to the adoption of colistin as a last-reserve antibiotic to counter infections that are resistant to carbapenems [1–3]. Hence, bacteria that are resistant to colistin are increasingly being reported worldwide [4–6]. Resistance to colistin is mediated by several molecular mechanisms, including the mobile colistin resistance (mcr) gene, mutations in the PmrAB and PhoPQ two-component systems, and mutation(s) in the MgrB regulator in Klebsiella pneumoniae [1,2,4,7]. These molecular mechanisms, alongside efflux hyperexpression and porin downregulation, and/or Ecr transmembrane protein mediate phenotype colistin (polymyxin) resistance and heteroresistance [1,8,9]. To help clinicians easily detect and monitor colistin-resistant infections, several diagnostic tests and assays, both commercial and non-commercial, have been designed and developed [3,10–12]. Some of these tests (such as the BMD, ComASPTM Colistin, MicroScan, Sensititre and Vitek) are mainly MIC (minimum-inhibitory concentration)-based, measuring only the MICs of the isolates while others are non-MIC—based, purely providing a binary result of resistant or sensitive (such as the CHROMagar COL-APSE, and Rapid NP test) [10–12]. The Rapid NP test was designed to only detect colistin resistance in *Enterobacterales* and is therefore not useful for all Gram-negative bacteria [10,13]. As a follow-up to previous research [11], we used 142 Gram-negative isolates and controls to evaluate the performance of six colistin resistance diagnostic tests: ComASP Colistin, CHROMagar COL-APSE, Rapid NP test, Sensititre, Vitek 2, and the MicroScan. The BMD remains the gold standard for testing colistin MICs and resistance in bacteria [10]; hence it was used as the reference standard in these evaluation studies.

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

METHODS Demographics and source of clinical specimen and isolates The evaluation study was conducted on a collection of 134 Gram-negative clinical bacterial (GNB) isolates including Enterobacterales (n=103), Acinetobacter baumannii (n=21) and Pseudomonas aeruginosa (n=10) that were collected from the National Health Laboratory Services, Tshwane Academic Division. Eight control strains were also included to make up to 142: Escherichia coli MC1, E. coli MC2, E. coli MC3, Salmonella group D MC4, Salmonella group D MC5, E. coli (mcr-1) EMRC, E. coli ATCC 25922 (EATCC), P. aeruginosa ATCC 27853 (PATCC). Species identification was performed as part of routine laboratory testing using Vitek® 2 automated system (Biomerieux, France) (Table S1). Demographic data such as sex, age and sample source were retrieved from the NHLS TrakCare system (Table S1). The National Food Institute, Technical University of Denmark provided five mcr-gene control strains (four E. coli with mcr-1, mcr-2, mcr-3 and mcr-4, as well as one Salmonella spp. with mcr-5) for this study. Antimicrobial susceptibility testing also included one Escherichia coli ATCC 25922 and one *P. aeruginosa* ATCC 27853. The labels of the isolates used in this article are known to only the researchers as the original labels were de-identified to maintain the patients anonymity. **Broth Microdilution**. The reference minimum inhibitory concentration (MIC) of each isolate was determined by manual broth microdilution (BMD) according to ISO standard 20776-1 [14]. Colistin sulfate powder (Glentham Life Sciences, England) was diluted in cationadjusted Mueller Hinton broth (CAMHB) in untreated 96-well microtiter polystyrene plates (Eppendorf, Germany). Dilutions to the MIC range 128-0.25 µg/mL were established. Colistin sensitivity results were interpreted according EUCAST breakpoints (susceptible

 $\leq 2 \Box \text{ mg/L}$; resistant $> 2 \Box \text{ mg/L}$). (https://www.nature.com/articles/s41598-020-63267-2).

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

Detection of mcr-genes. All isolates were screened for the presence of mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 genes using PCR. The multiplex PCR method previously described by Rebelo et al. was used for the screening of mcr-genes [15]. The mcr-gene control strains supplied by the kind courtesy of Professor Rene S. Hendriksen of the National Food Institute, Technical University of Denmark, were used as positive controls. Vitek 2 system. Besides species identification, the Vitek was also used to determine the MICs of the isolates, using the manufacturer's protocols. MicroScan. The MicroScan walkaway system (Beckman Coulter, South Africa) was used to determine the sensitivity of the species to colistin using the manufacturer's protocol. Briefly, an overnight culture grown on blood agar was immediately standardized using the the prompt inoculation system provided in the reagent packaging for MicroScan AST (antimicrobial sensitivity testing) and identification (ID) testing. The suspension was placed into the N66 and processed overnight in the MicroScan machine. ComASPTM Colistin. ComASPTM Colistin by Liofilchem (Roseto degli Abruzzi, Italy) is a compact panel containing freeze-dried colistin which when diluted should result in two-fold dilutions ranging from 0.25-16 µg/mL [11,16]. The non-automated BMD-based assay allows for four samples to be tested on a single test. The manufacturer's instructions were followed to perform the ComASPTM Colistin test. A 0.5 McFarland suspension of the isolates was prepared in a solution of 250 mL saline and then diluted to 1:20 in saline (Gibco, Thermo Fisher Scientific, USA) to obtain solution A. Solution A (0.4 mL) was added to a tube containing 3.6mL Mueller-Hinton broth provided by the ComASPTM Colistin to obtain solution B. One hundred microliters of solution B were dispensed into each well and the panels were incubated (Vacutec, US) at 36±2°C for 16 to 20 hours in ambient air. Results were read by visually analysing the plates for turbidity.

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

ChromAgar Col-APSE. Fresh 24-hour culture of each isolate was dissolved in saline and adjusted to 0.5 McFarland's standard. This suspension was spread on the ChromAgar Col-APSE plate and incubated for 18 - 24 hours. The manufacturer's protocol was used throughout this test (https://www.nature.com/articles/s41598-020-63267-2). SensititreTM. SensititreTM (Thermo Fisher Scientific, USA) "FROL" colistin-customised plates were used in this study. A 0.5 McFarland standard in saline was prepared for each isolate (Gibco, Thermo Fisher Scientific, USA). Ten microlitres of the 0.5 McFarland suspension was transferred into an 11 mL tube containing CAMHB with TES buffer for all non-intrinsic Enterobacterales, A. baumanni and P. aeruginosa isolates. However, for Proteus species, Providencia spp. and Morganella morganii 1 µL was transferred into the 11 mL CAMHB tube. Each SensititreTM plate constitutes of eight rows with 12 wells, each row allows for the testing of one isolate at different concentrations of colistin. Wells 1-11 contain dehydrated colistin at concentrations of 0.12-128 µg/mL, respectively. Well 12 represents a positive control and therefore does not contain colistin. Each well was inoculated with 50 µL of the bacterial broth suspension using a manual pipette. Each plate was then covered with an adhesive seal and incubated (Vacutec, US) at $\pm 35^{\circ}$ C in an aerobic environment. Results were read by visually analysing the plates for turbidity. In-house Rapid Polymyxin NP test. Rapid Polymyxin NP test is based on the detection of glucose metabolism related to Enterobacterales growth in the presence of a defined concentration of colistin [17]. The formation of acid metabolites is shown by a colour change of a pH indicator (red phenol) in less than 4 hours [17,18]. The rapid NP test was performed as described by Nordmann et al, 2016 [6,19-21]. To prepare the NP test solution, a 6.25g of CAMHB broth powder and 0.0125g of phenol red powder was added to 225 mL of distilled water. The pH of the solution was then adjusted to 6.7 by adding 1-N HCL in drops after which the solution was

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

autoclaved. A 25 mL of 10% anhydrous D-glucose solution that had been sterilised by filtration was added to the autoclaved CAMHB solution. Colistin stock solution (1280 μg/mL) was diluted to 200 μg/mL working solution by adding 1 mL of the stock solution to 5.4 mL CAMHB. To make colistin-NP test solution, 100 µL of the colistin working solution (200 µg/mL) was added to 3900 µL NP test solution to get a final concentration of 5 µg/mL. The Rapid Polymyxin NP test was carried out in 96 well polystyrene plates (Eppendorf, Germany). A 150 µL of NP test solution alone without colistin was added to wells 1, 3, 5, 7, 9 and 11 of each row (A-H) of the 96-well microtiter plates. Wells 2, 4, 6, 8, 10 and 12 contained 150 µL of colistin-NP test solution (5 µg/mL). Proteus mirabilis isolate from our collection was used as a resistant control and Escherichia coli ATCC 25922 was used as a susceptible control. A 3.5 McFarland standard was prepared for each test isolates with sterile 0.85% NaCl solution and used within 15 of preparation. Each *Enterobacterales* isolate was inoculated (50 μL) in parallel into the two wells, one without colistin and one with colistin. Wells H7-8 were inoculated 50 µL P. mirabilis and wells H9-10 were inoculated with 50 µL E. coli ATCC 25922. Wells H11-12 were inoculated with 50 µL of 0.85% NaCl solution. The microtiter plates were incubated for 3 h at 35 \(\perp \pm 2\), after 3 h of incubation, the isolates were checked for change in colour every 15 minutes until 4 h of incubation. The results were read visually where a change in colour of phenol red (orange to bright yellow) indicated growth. Data analysis All six antimicrobial susceptibility testing methods were compared to the ISO standard 20776-1 BMD. Colistin MIC results were interpreted using EUCAST's breakpoints (susceptible, $\leq 2 \mu g/mL$; resistant, $> 2 \mu g/mL$). For each test, the false positives, false negatives, true positives, and true negatives were determined and used for downstream determination of the other performance indices (Table S1). We calculated the rates of error (ME) using already described methods [11]. Categorical agreement was defined as an agreement in the classification of susceptible or resistant between the evaluated test and the reference BMD. Essential agreement was defined as an MIC value within a 2-fold (one doubling) dilution of the BMD result. A very major error occurred when the tested method interpretation of an isolate was susceptible while the BMD interpretation was resistant for the same isolate. A major error occurred when the investigated method's interpretation was resistant, and the BMD interpretation was susceptible for the same isolate. The sensitivity and specificity of each test were calculated as previously described [11].

GraphPad Prism 10 was used to calculate the odds ratio and Fisher's exact test to determine the significance of each test's results against the BMD.

RESULTS

Reference BMD. Reference MICs of all 142 isolates were determined by standard broth microdilution (BMD), either in this study or as standard protocol by the National Health Laboratory Services Tshwane Academic Division. One A. baumannii, 51 Enterobacterales and seven P. aeruginosa isolates were colistin-susceptible with BMD, including one E. coli ATCC 25922 and a P. aeruginosa ATCC 27853 (Table 1). The colistin-resistant isolates by BMD include 59 Enterobacterales, 20 A. baumannii and four P. aeruginosa. Apart from the five mcr control strains, only two isolates, BB2 and EMRC, had mcr-1 genes (Table 1). Isolate BB2 is an A. baumannii with a MIC of 32 μ g/mL, while isolate EMRC is an E. coli with a MIC of 4 μ g/mL. All eight intrinsically colistin-resistant Enterobacterales (Proteus mirabilis, Serratia marcescens, Morganella morganii, Proteus vulgaris, Providencia stuartii, and Ralstonia/Burkholderia pickettii) had MICs \geq 128 μ g/mL (Table 1).

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

Commercial BMD methods. All 142 isolates were tested on ComASPTM Colistin and SensititreTM. ComASPTM Colistin and SensititreTM both had a satisfactory categorical agreement of 96.48% and 97.18%, respectively. However, ComASPTM Colistin falsely detected one K. pneumoniae (1µg/mL) and one P. aeruginosa (1µg/mL) as colistinsusceptible isolates, resulting in 3.40% MEs. SensititreTM accurately identified all colistinsusceptible isolates. However, it failed to identify three colistin-resistant isolates, therefore resulting in no MEs and 3.61% VMEs. Most isolates that were not detected by SensititreTM and ComASPTM Colistin had MICs close to the breakpoints (4-8µg/mL). Only one isolate that was not detected by SensititreTM had an MIC >8 μg/mL i.e., a K. pneumoniae with an MIC of 32µg/mL. ComASPTM Colistin had an overall sensitivity and specificity of 96.39% and 96.61%, respectively, whereas SensititreTM had 96.39% and 100% (Table 2). Notably, ComASPTM fared better with *Enterobacterales* than with all Gram-negative bacteria as its sensitivity (98.31%), specificity (98.04%), and CA (98.18%) increased while its ME (1.96%) and VMEs (1.72%) reduced (Table 2): the EA, however, increased from 69.09% in Enterobacterales to 75.35% in GNB. Sensititre's Enterobacterales results were comparably similar to that of its GNB results (Table 2). Vitek MIC results were obtained for 120 GNB and 94 Enterobacterales. Vitek had the highest sensitivity and the second or third highest specificity among GNB and Enterobacterales, respectively, for all the tests. It had the highest CA, the second lowest EA (after MicroScan), and one of the lowest VME among the six tests (Table 2). The Microscan was equally highly sensitive but less specific, with the lowest EA (46.11% and 46.91%) among all the MICbased tests. Its sensitivity was 96.55% and 100% for GNB and Enterobacterales respectively. The MicroScan's MEs with both GNB and Enterobacterales (12.50% and 12.20%) were only

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

second to that of the CHROMAgar Col-APSE (Table 2) and its VMEs were 3.45% (GNB) and 0% (*Enterobacterales*). CHROMAgar Col-APSE. A total of 96/142 isolates grew on CHROMAgar Col-APSE: BMD identified 19 of them as colistin susceptible, resulting in 32.20% ME and 67.80% specificity. Most of the MEs (14/19) were due to Klebsiella spp. The chromogenic media detected most colistin-resistant isolates (77/83), but it also produced a high percentage of VMEs (7.23%), resulting in a sensitivity of 92.77 %. Among Enterobacterales alone, CHROMAgar was less sensitive (91.53%) and more specific (68.63%), with fewer MEs (31.37%) and CA (80.91%) than in GNB (Table 2). Differentiation of the isolated bacteria by the morphological appearance of their colonies was as described by the manufacturer [22]. Metallic blue (Klebsiella, Enterobacter and Serratia spp.), cream white (Acinetobacter, Salmonella and Pseudomonas spp.), pink-red (E. coli) colonies were observed (Fig. 1) [22]. Furthermore, E. coli could be distinguished as fermenting (blue with pink borders) and non-fermenting strains (pink). Swarming was observed on the P. mirabilis-inoculated plate because the plate was not supplemented with pnitrophenyl glycerol as recommended by Abdul Momin et al (2017) (Figure 1) [22]. **In-house Rapid NP Test.** Only 102/142 of the isolates that were *Enterobacterales* were included in this test. This included 51 colistin-susceptible and 51 non-intrinsically colistinresistant Enterobacterales isolates. The overall sensitivity and specificity of the in-house Rapid polymyxin NP test was 92.16% and 96.08% respectively. Colistin-resistant isolates that were not detected include one Salmonella spp., two K. pneumoniae and one E. coli, with MICs ranging from $4 - 128 \mu g/mL$. Two of the false-resistant isolates, also grew on CHROMAgar Col-APSE (Table S1). In this study, most results were positive within two hours of incubation. Six isolates, however, were not detectable after three hours of incubation

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

but were positive after four hours. Amongst the slow-growing isolates were four Salmonella spp., one E. coli, and one E. cloacae. **DISCUSSION** The proliferation of colistin resistance among GNB has necessitated the development of better diagnostics to quickly and efficiently detect colistin-resistant organisms to control their spread [1,2,4,10,11]. This study evaluated six antimicrobial susceptibility tests that were developed to detect colistin-resistance with efficiency. Broth microdilution is currently the golden standard for colistin susceptibility testing; however, it is considered tedious and difficult [10]. Vitek 2, ComASPTM Colistin, and MicroScan had the best detection (sensitivity) of colistin-resistant isolates (Table 2). When compared with SensititreTM, CHROMagar Col-APSE, the Rapid Polymyxin NP test, ComASPTM Colistin, and MicroScan, Vitek 2 produced the least VMEs at 1.25% and 0% for GNB and Enterobacterales, respectively. This was followed by the MicroScan and ComASP, with VMEs of 3.45% vrs 3.57% and 0% vrs 1.96% respectively for all isolates and *Enterobacterales* (Table 2). In essence, the Vitek 2, which is common in many well-resourced routine diagnostic microbiology laboratories, is very efficient in detecting colistin resistance albeit its low EA should be considered when using MICs from Vitek 2. Moreover, its initial cost, long turnaround time, and skill required to operate it make it inaccessible to low-resourced

laboratories. Although the MicroScan is also highly sensitive with low VMEs (particularly among *Enterobacterales*), its lower specificity and EA, 18-24-hour turnaround time, operating skill required, and initial cost are also major disadvantages for low-resourced laboratories [10–12]. The ComASP and Sensititre are two affordable commercial kits that can be adopted in low-resourced laboratories for colistin resistance diagnosis. The Sensititre had

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

100% specificity and 72.54% vrs 71.82% EA for both GNB and Enterobacterales, which were the best (with ComASP) among all the six tests. Hence, in terms of cost and required skill, the Sensititre and ComASP are good alternatives for determining the colistin MICs and resistance. The EA recorded in this study for both commercial BMD methods is below the recommended EA (≥ 90%) for antimicrobial susceptibility testing systems. The EA did not improve when analysing Enterobacterales alone for ComASPTM Colistin, MicroScan, and SensititreTM; Vitek 2, however, had an increase from 57.50% (Gram-negative bacteria) to 59.78% (Enterobacterales) (Tables 1-2). ComASPTM Colistin tended to decrease or increase the MIC of a significant number of colistin-susceptible isolates (29/59) by one two-fold dilution (Table S1). Notwithstanding, this observation did not change the CA between ComASPTM Colistin and the reference BMD. In this study, CHROMAgar Col-APSE produced the highest rate of MEs and a high VME second only to that of the in-house Rapid NP test (Tables 1-2), particularly for *Klebsiella* spp. Although the specificity recorded in this study and that of Osei Sekvere *et al* (at 66.67%) agree, two other studies recorded a significantly higher specificity of $\geq 97\%$ [11,22,23]. These discrepancies could be attributed to the different bacterial inoculum concentrations used. Ali et al demonstrated that when a 0.5 McFarland standard inoculum was used, colistinsusceptible isolates were able to grow on the media [23], whereas the same isolates were inhibited when the inoculum was diluted to a density of 1×10⁵ CFU/mL. Therefore, the high rate of MEs in this present study could be due to the inoculum used being a 0.5 McFarland standard (1.5 \times 10⁸ CFU).

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

The in-house Rapid Polymyxin NP test was expected to have the best performance for Enterobacterales. Even though the test was designed specifically for colistin susceptibility testing on Enterobacterales, its performance was inferior to that of commercial BMD methods (Tables 1-2). Compared with other studies that have achieved a sensitivity of $\geq 97\%$, the overall performance of the in-house Rapid Polymyxin in this study (~92%) is slightly poor [17,18,24]. The CA of all the tests evaluated in this study except for CHROMAgar Col-APSE, is within the recommended standard (≥ 90%) for antimicrobial susceptibility testing systems. Nevertheless, except for Vitek 2 for all GNB and MicroScan in only Enterobacterales, all the other evaluated tests had an unacceptable VME rate of $\geq 1.5\%$. Only SensititreTM had an acceptable rate of MEs when all isolates were considered, but ComASPTM Colistin's ME improved when only *Enterobacterales* were examined. Therefore, for low-resourced laboratories and research institutions, the in-house Rapid NP test is a better option in terms of turnaround time, cost, and efficiency than the CHROMAgar COL-APSE, except that the latter has advantages of easy use and species identification through its chromogenic compounds. In terms of cost and turnaround time, the CHROMAgar is comparable to the two other commercial MIC tests: Sensititre and ComASP. Nevertheless, the higher efficiency of the former two and their ability to provide actual MICs make them recommendable. Yet, CHROMAgar is easier to use than these two MIC tests and the MICs of ComASP should be used with caution among *Enterobacterales* owing to its 75.35% EA. The statistical odd ratio and p-values metrics indicate that the tests, specifically the Vitek 2, SensititreTM, ComASPTM Colistin, MicroScan, and the in-house Rapid NP test, have a relatively high level of performance in identifying both resistant and sensitive isolates among GNB. The PPV and NPV suggest that the tests' predictive values are highly reliable. The

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

odds ratio suggests a very strong association between the test results and the resistance being tested for, indicating that the likelihood of detecting resistant isolates is significantly higher when they are truly resistant, as compared to when they are not. The extremely low p-value indicates that this finding is statistically significant, meaning there's a very small chance that these results could have occurred by random variation alone. **CONCLUSION** This study discovered that commercial BMD methods had the best overall performance. In the absence of resources to purchase the Vitek 2 or the MicroScan, we recommend the ComASPTM Colistin and SensititreTM as potential alternative MIC tests for routine colistin antimicrobial susceptibility testing in clinical laboratories. However, isolates with MICs close to the breakpoint may be misinterpreted by commercial BMD tests. As the in-house Rapid NP test had the quickest turnaround time, we recommend it for colistin susceptibility testing on Enterobacterales, particularly in laboratories with limited resources and labour skill. Notably, CHROMAgar Col-APSE produced the most errors; with colistin being a last-reserve antibiotic, minimal error is critical. Hence, the use of CHROMAgar Col-APSE should be validated further, possibly with lower inoculum. Notably, all the tests were able to detect colistin resistance in *mcr*-positive strains. **Acknowledgements:** We are grateful to the staff of the NHLS-TAD for their support and assistance in collecting and plating the isolates. We hereby regretfully report the death of our colleague Professor Nontombi Marylucy Mbelle, who died during the course of this investigation. This work is dedicated to her memory. We are ever grateful to Professor Rene S. Hendriksen, Ana Rita Bastos Rebelo, and Troels Ronco of the National Food Institute, Technical University of Denmark, for their donation of the mcr-1 to mcr-5 positive controls.

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376


377

Funding: This work was funded by a grant from the National Health Laboratory Service (NHLS) given to Dr. John Osei Sekyere under grant number GRANT004 94807 and GRANT004 94808. **Transparency declaration:** The authors declare no conflict of interest. Author contributions: TMSL undertook the laboratory investigations, undertook initial analysis of the data and drafted the manuscript. MM assisted with the laboratory work. BLS assisted with isolates collection and plating. NMM co-supervised the study. JOS designed and supervised the study, undertook data analysis, and wrote the manuscript. All authors reviewed the final version of the manuscript. **Ethical approval:** The study was approved by the Research Ethics Committee, Faculty of Health Sciences, University of Pretoria, under reference number 550/2020. The study complied with the ICH-GCP guidelines and the Helsinki declaration. References Mmatli M, Mbelle NM, Maningi NE, Osei Sekyere J. Emerging Transcriptional and Genomic [1] Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae□: a Systematic Review of Current Reports. MSystems 2020;5. https://doi.org/10.1128/mSystems.00783-20. [2] Mmatli M, Mbelle NM, Osei Sekyere J. Global epidemiology, genetic environment, risk factors and therapeutic prospects of mcr genes: A current and emerging update. Front Cell Infect Microbiol 2022;12. https://doi.org/10.3389/fcimb.2022.941358. Mmatli M, Leshaba TMS, Skosana LB, Mbelle NM, Osei Sekyere J. Molecular Screening of Clinical [3] Multidrug-Resistant Gram-Negative Bacteria Shows Endemicity of Carbapenemases, Coexistence of Multiple Carbapenemases, and Rarity of mcr in South Africa. Microb Drug Resist 2022;28:1028–36. https://doi.org/10.1089/MDR.2022.0112. [4] Ramaloko WT, Osei Sekyere J. Phylogenomics, epigenomics, virulome and mobilome of Gram-negative bacteria co-resistant to carbapenems and polymyxins: a One Health systematic review and metaanalyses. Environ Microbiol 2022;24:1518-42. https://doi.org/10.1111/1462-2920.15930. [5] Lowe M, Shuping L, Perovic O. Carbapenem-resistant Enterobacterales in patients with bacteraemia at tertiary academic hospitals in South Africa, 2019 - 2020: An update. South African Med J 2022;112:545–52. https://doi.org/10.7196/SAMJ.2022.V112I8.16351. [6] Jayol A, Dubois V, Poirel L, Nordmann P. Rapid Detection of Polymyxin-Resistant Enterobacteriaceae from Blood Cultures. J Clin Microbiol 2016;54:2273–7. https://doi.org/10.1128/JCM.00918-16. [7] Osei Sekyere J, Reta MA, Fourie PB. Risk factors for, and molecular epidemiology and clinical outcomes of, carbapenem- and polymyxin-resistant Gram-negative bacterial infections in pregnant women, infants, and toddlers: a systematic review and meta-analyses. Ann N Y Acad Sci 2021:1-18. https://doi.org/10.1111/nyas.14650.

378 379 380	[8]	Halaby T, Kucukkose E, Janssen AB, Rogers MRC, Doorduijn DJ, van der Zanden AGM, et al. Genomic Characterization of Colistin Heteroresistance in Klebsiella pneumoniae during a Nosocomial Outbreak. Antimicrob Agents Chemother 2016;60:6837–43. https://doi.org/10.1128/AAC.01344-16.
381 382 383	[9]	Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes. Clin Microbiol Rev 2017;30:557–96. https://doi.org/10.1128/CMR.00064-16.
384 385 386	[10]	Leshaba TMS, Mbelle NM, Osei Sekyere J. Current and emerging polymyxin resistance diagnostics: a systematic review of established and novel detection methods. J Appl Microbiol 2021:jam.15184. https://doi.org/10.1111/jam.15184.
387 388 389	[11]	Osei Sekyere J, Sephofane AK, Mbelle NM. Comparative Evaluation of CHROMagar COL-APSE, MicroScan Walkaway, ComASP Colistin, and Colistin MAC Test in Detecting Colistin-resistant Gram-Negative Bacteria. Sci Rep 2020;10:1–13. https://doi.org/10.1038/s41598-020-63267-2.
390 391	[12]	Osei Sekyere J. Mcr colistin resistance gene: a systematic review of current diagnostics and detection methods. Microbiologyopen 2019;8:e00682. https://doi.org/10.1002/mbo3.682.
392 393 394	[13]	Jayol A, Nordmann P, Lehours P, Poirel L, Dubois V. Comparison of methods for detection of plasmid-mediated and chromosomally encoded colistin resistance in Enterobacteriaceae. Clin Microbiol Infect 2017;pii:S1198-:30291–4. https://doi.org/10.1016/j.cmi.2017.06.002.
395 396 397 398 399	[14]	International Organization for Standardization. Susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices - Part 1: Broth micro-dilution reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobi. Biol Eval Med Devices 2019:19. https://www.iso.org/obp/ui/#iso:std:iso:20776:-1:ed-2:v2:en (accessed March 19, 2024).
400 401 402 403	[15]	Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, Hansen IM, et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes. Euro Surveill Bull Eur Sur Les Mal Transm = Eur Commun Dis Bull 2018;23. https://doi.org/10.2807/1560-7917.ES.2018.23.6.17-00672.
404 405 406	[16]	Carretto E, Brovarone F, Russello G, Nardini P, El-Bouseary MM, Aboklaish AF, et al. Clinical validation of SensiTest colistin, a broth microdilution-based method to evaluate colistin MICs. J Clin Microbiol 2018;56. https://doi.org/10.1128/JCM.01523-17.
407 408	[17]	Nordmann P, Jayol AAAA, Poirel L. Rapid Detection of Polymyxin Resistance in Enterobacteriaceae. Emerg Infect Dis 2016;22:1038–43. https://doi.org/10.3201/eid2206.151840.
409 410 411	[18]	Mitton B, Kingsburgh C, Kock MM, Mbelle NM, Strydom K. Evaluation of an In-House Colistin NP Test for Use in Resource-Limited Settings. J Clin Microbiol 2019;57. https://doi.org/10.1128/JCM.00501-19.
412 413 414	[19]	Poirel L, Larpin Y, Dobias J, Stephan R, Decousser J-W, Madec J-Y, et al. Rapid Polymyxin NP test for the detection of polymyxin resistance mediated by the mcr-1/mcr-2 genes. Diagn Microbiol Infect Dis 2017;90:7–10. https://doi.org/10.1016/j.diagmicrobio.2017.09.012.
415 416 417	[20]	Jayol AAA, Kieffer N, Poirel L, Guerin F, Guneser D, Cattoir V, et al. Evaluation of the Rapid Polymyxin NP test and its industrial version for the detection of polymyxin-resistant Enterobacteriaceae. Diagn Microbiol Infect Dis 2018;92:90–4. https://doi.org/10.1016/j.diagmicrobio.2018.05.006.
418 419 420	[21]	Nordmann P, Assouvie L, Prod'Hom G, Poirel L, Greub G. Screening of plasmid-mediated MCR-1 colistin-resistance from bacteremia. Eur J Clin Microbiol Infect Dis 2016;35:1891–2. https://doi.org/10.1007/s10096-016-2739-0.
421 422 423	[22]	Abdul Momin MHF, Bean DC, Hendriksen RS, Haenni M, Phee LM, Wareham DW. CHROMagar COL-APSE: a selective bacterial culture medium for the isolation and differentiation of colistin-resistant Gram-negative pathogens. J Med Microbiol 2017;66:1554–61. https://doi.org/10.1099/jmm.0.000602.

[23] Ali S, Hussain W, Ahmed F, Afzal RK, Mirza I, Khurshid U. ChromagarTM Col-Apse for Detection of Colistin Resistance in Clinical Isolates of Multidrug Resistant Gram Negative Bacilli. J Coll Physicians Surg Pak 2022;32:177–80. https://doi.org/10.29271/JCPSP.2022.02.177.

[24] Germ J, Seme K, Cerar T, Krizan Hergouth V, Pirs M. Evaluation of two rapid phenotypical tests-Alifax rapid AST colistin test and Rapid Polymyxin NP test-for detection of colistin resistance in Enterobacterales. Eur J Clin Microbiol Infect Dis 2021;40:1749–53. https://doi.org/10.1007/S10096-021-04182-W.






Figure 1. Appearance of different bacterial species on the CHROMAgar-col *APSE* chromogenic media. (A) Bacterial growth on CHROMAgar Col-*APSE* showing different colony colours. (B) Swarming by *P. mirabilis* on CHROMAgar Col-*APSE*

Table S1. Demographics, species, complete antibiotic resistance results data, and minimum inhibitory concentrations (MICs) of the isolates used in this study.

